Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study

MLA

Stolz D, et al. “Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study.” Journal of Asthma and Allergy, vol. ume 17, Dec. 2024, pp. 1301–12. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.53049f6831034aa7b5db74ecffe6218c&authtype=sso&custid=ns315887.

APA

Stolz D, Schuoler C, Charbonnier F, Bridevaux PO, Jandus P, Leuppi JD, Pavlov N, Piecyk A, & Rothe T. (2024). Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study. Journal of Asthma and Allergy, ume 17, 1301–1312.

Chicago

Stolz D, Schuoler C, Charbonnier F, Bridevaux PO, Jandus P, Leuppi JD, Pavlov N, Piecyk A, and Rothe T. 2024. “Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study.” Journal of Asthma and Allergy ume 17 (December): 1301–12. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.53049f6831034aa7b5db74ecffe6218c&authtype=sso&custid=ns315887.